Freenome
Freenome raises $290M Series D at $1.1B valuation
Quick Facts
Freenome: Series D Funding Round
Freenome has successfully raised $290M in Series D funding, reaching a valuation of $1.1B.
Company Overview
AI-driven early cancer detection
Funding Details
The Series D round was led by Perceptive Advisors, with participation from RA Capital Management, Andreessen Horowitz, GV, T. Rowe Price, Roche Venture Fund.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2014
- Employees: 400+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Perceptive Advisors: Verified investor in Series D
- RA Capital Management: Verified investor in Series D
- Andreessen Horowitz: Verified investor in Series D
- GV: Verified investor in Series D
- T. Rowe Price: Verified investor in Series D
- Roche Venture Fund: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...